J. THOMAS BIGGER JR., M.D.; JAMES COROMILAS, M.D.
Several large, double-blind, randomized, placebo-controlled clinical trials have shown that beta-adrenergic blocking drugs reduce the mortality rate and incidence of nonfatal myocardial infarction in the first 2 years after myocardial infarction (1). The most impressive evidence of their benefit comes from the Beta-Blocker Heart Attack Trial (2) and a Norwegian trial with timolol (3). Both studies were analyzed by the intention-to-treat principle, even though dropout rates were substantial (4).
In the Norwegian study (3), 1884 patients were randomly assigned to receive placebo or timolol maleate, 10 mg twice daily, 7 to 28 days after infarction, and continued treatment for an
Learn more about subscription options.
Register Now for a free account.
BIGGER JT, COROMILAS J. How Do Beta-Blockers Protect After Myocardial Infarction?. Ann Intern Med. 1984;101:256–258. doi: 10.7326/0003-4819-101-2-256
Download citation file:
Published: Ann Intern Med. 1984;101(2):256-258.
Acute Coronary Syndromes, Cardiology, Coronary Risk Factors, Emergency Medicine, HIV.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only